二苯甲基膦酸 | 7526-26-3

• 物质功能分类: 有机原料 - 无机酸酯
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 二苯甲基膦酸
• 中文别名: 磷酸甲基二苯基酯
• 英文名称: diphenyl methylphosphonate
• 英文别名: methyl phosphonic acid diphenyl ester；[methyl(phenoxy)phosphoryl]oxybenzene
• CAS: 7526-26-3
• 化学式: C₁₃H₁₃O₃P
• 分子量: 248.218
• InChiKey: HPUPGAFDTWIMBR-UHFFFAOYSA-N

物化性质

• 熔点：
  32.5-37.5 °C(lit.)
• 沸点：
  151 °C(Press: 0.8 Torr)
• 密度：
  1.21 g/mL at 25 °C(lit.)
• 闪点：
  230 °F
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）
• LogP：
  2.8 at 30℃
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 储存条件：
  密封在阴凉干燥的环境中。

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name Diphenyl Methylphosphonate
Portland OR
Methylphosphonic Acid Diphenyl Ester
Synonym
C13H13O3P
Chemical Formula
CAS Number 7526-26-3

---

Section II. Composition and Information on Ingredients
Chemical Name CAS Number Percent (%) TLV/PEL Toxicology Data
Diphenyl Methylphosphonate 7526-26-3 Min. Not available. Rat LD50 (oral) 233 mg/kg
98.0%(GC)

---

Section III. Hazards Identification
Acute Health Effects Toxic if ingested or inhaled. Avoid prolonged contact with this material. Overexposure may result in serious illness or
death.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Chronic Health Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated exposure to an highly toxic material may produce general deterioration of health by an accumulation in one or
many human organs.

---

Section IV. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing
and shoes. Wash clothing before reuse. Thoroughly clean shoes before reuse. Get medical attention immediately.
Inhalation If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Ingestion
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the
toxic material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Auto-Ignition Not available.
Flammability May be combustible at high temperature.
Flash Points Flammable Limits Not available.
110°C (230°F).
Combustion Products These products are toxic carbon oxides (CO, CO2), phosphates.
Fire Hazards
Not available.
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
Diphenyl Methylphosphonate

---

Section VI. Accidental Release Measures
Spill Cleanup Toxic Material.
Stop leak if without risk. If the product is in its solid form: Use a shovel to put the material into a convenient waste
Instructions
disposal container. If the product is in its liquid form: DO NOT get water inside container. Absorb with an inert material
and put the spilled material in an appropriate waste disposal. DO NOT touch spilled material. Use water spray to reduce
vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Eliminate all sources of ignition.
Consult federal, state, and/or local authorities for assistance on disposal.

---

Section VII. Handling and Storage
Handling and Storage TOXIC. Keep locked up.. Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the
container and store in a dry, cool place. Avoid excessive heat and light. DO NOT ingest. Do not breathe dust. Wear
Information
suitable protective clothing. If ingested, seek medical advice immediately and show the container or the label. Treat
symptomatically and supportively.
Always store away from incompatible compounds such as oxidizing agents, alkalis (bases).

---

Section VIII. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Splash goggles. Lab coat. Dust respirator. Boots. Gloves. A MSHA/NIOSH approved respirator must be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling
this product.
Exposure Limits Not available.

---

Section IX. Physical and Chemical Properties
Solid. (White Crystals and Lumps.) Solubility
Physical state @ 20°C Not available.
1.21 (water=1)
Specific Gravity
Molecular Weight 248.21 Partition Coefficient Not available.
Boiling Point
Not available. Vapor Pressure Not applicable.
Melting Point 32.5 to 37.5°C (90.5 to 99.5°F) Vapor Density Not available.
Refractive Index Not available. Volatility Not available.
Critical Temperature Not available. Odor Not available.
Viscosity Not available. Taste Not available.

---

Section X. Stability and Reactivity Data
Stability

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Conditions of Instability Avoid excessive heat and light.
Incompatibilities
Reactive with strong oxidizing agents, strong alkalis (bases).

---

Section XI. Toxicological Information
RTECS Number SZ9127500
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Toxicity Data Rat LD50 (oral) 233 mg/kg
CARCINOGENIC EFFECTS : Not available.
Chronic Toxic Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated exposure to an highly toxic material may produce general deterioration of health by an accumulation in one or
many human organs.
Toxic if ingested or inhaled. Avoid prolonged contact with this material. Overexposure may result in serious illness or
Acute Toxic Effects
death.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Continued on Next Page
Diphenyl Methylphosphonate

---

Section XII. Ecological Information
Ecotoxicity Not available.
Not available.
Environmental Fate

---

Section XIII. Disposal Considerations
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
Waste Disposal
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
DOT Classification DOT Class 6.1: Toxic material.
PIN Number
Proper Shipping Name
Toxic solid, organic, n.o.s
Packing Group (PG) III
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This compound is ON the EPA Toxic Substances Control Act (TSCA) inventory list.
(EPA)
WHMIS Classification CLASS D-1B: Material causing immediate and serious toxic effects (TOXIC).
On NDSL.
(Canada)
EINECS Number (EEC) 231-388-1
EEC Risk Statements
R23/24/25- Toxic by inhalation, in contact with skin and if swallowed.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  二苯甲基膦酸 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以40%的产率得到甲基膦酰氟
  参考文献：
  名称：

  Direct ¹⁸F-Labeling of Biomolecules via Spontaneous Site-Specific Nucleophilic Substitution by F^– on Phosphonate Prostheses

  摘要：

  DOI：

  10.1021/acs.orglett.1c01211
• 作为产物：
  描述：

  二苯基亚磷酸甲酯 在 三氟甲磺酸 作用下， 反应 16.0h， 以82%的产率得到二苯甲基膦酸
  参考文献：
  名称：

  水决定了产物：意外的布朗斯台德酸催化P（III）酯的PO-R裂解，选择性地产生P（O）-H和P（O）-R化合物

  摘要：

  发现水能够确定布朗斯台德酸催化的亚磷酸三烷基酯的C-O裂解反应的选择性：与水一起，该反应在室温下迅速发生，从而定量获得H-膦酸酯的收率。在不加水的情况下，该反应选择性地以高收率提供了烷基膦酸酯，为著名的Michaelis-Arbuzov反应提供了一种新型的无卤化物替代方案。该方法是通用的，因为它可以很容易地扩展到亚膦酸酯和次膦酸酯以及大规模的反应，而催化剂的负载却低得多，从而能够简单，有效和实用地制备相应的有机磷化合物。

  DOI：

  10.1039/c9gc01254k
• 作为试剂：
  描述：

  苯乙炔 、 Diphenylphosphine oxide 在 tris-(dibenzylideneacetone)dipalladium(0) 、 二苯甲基膦酸 、 1,2-双(二苯基膦)乙烷 作用下， 以 甲苯 为溶剂， 以84 %的产率得到diphenyl(1-phenylvinyl)phosphine oxide
  参考文献：
  名称：

  醛的三组分直接磷酸化和酮的烷基化：酸性条件下γ-酮氧化膦的合成

  摘要：

  开发了一种有效且经济的酸促进三组分反应，用于构建 C-P 和 C-C 键，用于合成 γ-酮膦氧化物，水作为唯一的副产物。详细的机理实验证实，该反应通过磷醛醇消除进行，其中醛的磷酸化产生苄基碳正离子，然后在酸性条件下与酮烯醇化物反应。

  DOI：

  10.1021/acs.joc.3c01674

文献信息

• DBU-promoted alkylation of alkyl phosphinates and H-phosphonates
  作者：Laurent Gavara、Christelle Petit、Jean-Luc Montchamp

  DOI：10.1016/j.tetlet.2012.07.019

  日期：2012.9

  phosphinates and some H-phosphonate diesters is promoted by the base DBU. Only more reactive alkyl halides react in preparatively useful yields. However, the method provides easy access to important H-phosphinate building blocks, without the need for a protecting group strategy or metal catalysts. The reaction is conveniently conducted at, or below, room temperature. The preparation of methyl-H-phosphinate

  DBU碱促进烷基次膦酸酯和一些H-膦酸酯二酯的烷基化。只有更多的反应性烷基卤化物以制备有用的产率反应。但是，该方法无需重要的保护基策略或金属催化剂即可轻松获得重要的H-次膦酸酯结构单元。该反应方便地在室温或低于室温下进行。甲基的制备ħ -phosphinate酯是特别令人感兴趣的，因为它避免了以往更普遍使用methyldichlorophosphine MePCl的2。
• Phosphorus-containing hepatitis C serine protease inhibitors
  申请人：Moore Joel D.

  公开号：US20080039375A1

  公开（公告）日：2008-02-14

  The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I或式II的磷衍生化合物，或其药用可接受的盐、酯或前药，这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的主体进行管理。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。
• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• [EN] NRF2 REGULATORS<br/>[FR] RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016202253A1

  公开（公告）日：2016-12-22

  Provided are aryl analogs，pharmaceutical compositions containing them and their use as NRF2 regulators.

  提供芳基类似物，含有它们的药物组合物以及它们作为NRF2调节剂的用途。
• [EN] AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS<br/>[FR] LIBÉRATION CONTRÔLÉE DE L'AMPHÉTAMINE, PROMÉDICAMENT ET FORMES POSOLOGIQUES DISSUASIVES DU MÉSUSAGE
  申请人：CHEMAPOTHECA LLC

  公开号：WO2017147375A1

  公开（公告）日：2017-08-31

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的，以及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的苯丙胺化合物的制造、输送和使用方法。

表征谱图